Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $11.0 million.

  • Viridian Therapeutics, Inc.\DE's Prepaid Assets fell 2191.73% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 2191.73%. This contributed to the annual value of $20.9 million for FY2024, which is 13181.21% up from last year.
  • Viridian Therapeutics, Inc.\DE's Prepaid Assets amounted to $11.0 million in Q3 2025, which was down 2191.73% from $15.4 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Prepaid Assets high stood at $20.9 million for Q4 2024, and its period low was $2.7 million during Q4 2021.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Prepaid Assets had a median value of $9.0 million in 2023 and averaged $9.4 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Prepaid Assets skyrocketed by 18082.8% in 2023, and later plummeted by 2191.73% in 2025.
  • Viridian Therapeutics, Inc.\DE's Prepaid Assets (Quarter) stood at $2.7 million in 2021, then surged by 137.39% to $6.5 million in 2022, then skyrocketed by 38.11% to $9.0 million in 2023, then skyrocketed by 131.81% to $20.9 million in 2024, then crashed by 47.25% to $11.0 million in 2025.
  • Its Prepaid Assets stands at $11.0 million for Q3 2025, versus $15.4 million for Q2 2025 and $20.6 million for Q1 2025.